<code id='867CD4A4CB'></code><style id='867CD4A4CB'></style>
    • <acronym id='867CD4A4CB'></acronym>
      <center id='867CD4A4CB'><center id='867CD4A4CB'><tfoot id='867CD4A4CB'></tfoot></center><abbr id='867CD4A4CB'><dir id='867CD4A4CB'><tfoot id='867CD4A4CB'></tfoot><noframes id='867CD4A4CB'>

    • <optgroup id='867CD4A4CB'><strike id='867CD4A4CB'><sup id='867CD4A4CB'></sup></strike><code id='867CD4A4CB'></code></optgroup>
        1. <b id='867CD4A4CB'><label id='867CD4A4CB'><select id='867CD4A4CB'><dt id='867CD4A4CB'><span id='867CD4A4CB'></span></dt></select></label></b><u id='867CD4A4CB'></u>
          <i id='867CD4A4CB'><strike id='867CD4A4CB'><tt id='867CD4A4CB'><pre id='867CD4A4CB'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:39555

          Does biotech prepare you for the presidency? Who really wants to gut the FDA? And why do drug companies struggle with IT?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.

          advertisement

          For more on what we cover, here’s more on Ramaswamy; here’s the news on the data leak; here’s the story on the latest Langer venture; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Biotech investment managers search for lucrative opportunities
          Biotech investment managers search for lucrative opportunities

          Fromleft,RodNathan,portfoliomanagerandpartnerofJ.Goldman&Co.;ARKInvestsenioranalystAliUrman;andP

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Yancopoulos of Regeneron works to expand Dupixent success

          GeorgeYancopoulosonthe2024BreakthroughSummitEaststageSTATGeorgeYancopoulosisintouchwithhisteenagesel